BioNxt Solutions Inc. Extends Convertible Debentures and Issues Warrants

BioNxt Solutions Inc., a bioscience company listed on multiple exchanges including CSE and OTCQB, has announced amendments to its unsecured convertible debentures. The debentures, with a combined principal of several million dollars and an 8% interest rate, were initially set to mature between November 2026 and March 2027. These maturities have now been extended by one year.

As compensation for the extension, BioNxt will issue 16,900,000 common share purchase warrants to debenture holders. Each warrant permits the purchase of a common share for $0.50 within a year of issuance. These transactions await the necessary regulatory approvals.

The issued warrants and any shares derived from them are subject to a hold period as per securities legislation. More details on terms and conditions can be found in previous news releases or on the company's profiles on public platforms.